SCHEMBL3370139

SCHEMBL3370139

O=S(=O)(Cc1ccc(F)c(Cl)c1)N1CCCC1c1nnc(-c2ccc(-c3ccccc3)cc2)o1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 1/20 0.43
DPP4 P27487 1/20 0.43
HDAC1 Q13547 4/20 0.40
KDM4E B2RXH2 2/20 0.39
HPGD P15428 2/20 0.39
ALDH1A1 P00352 1/20 0.39
TNKS O95271 1/20 0.39
PARP1 P09874 1/20 0.39
PARP2 Q9UGN5 1/20 0.39
HSD11B1 P28845 1/20 0.39
HCRTR1 O43613 2/20 0.38
HCRTR2 O43614 2/20 0.38
MAPT P10636 5/20 0.38
LMNA P02545 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
HDAC6 Q9UBN7 2/20 0.38
TP53 P04637 1/20 0.38
CYP3A4 P08684 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3370219 0.89 KDM4E (0.49) USP30DPP4KDM4EHPGDALDH1A1
SCHEMBL3367323 0.84 MAPK1 (0.39) KDM4EHPGDALDH1A1LMNASMN1; SMN2
SCHEMBL3366848 0.84 ALDH1A1 (0.48) KDM4EHPGDALDH1A1HSD11B1MAPT
SCHEMBL3366972 0.79 USP30 (0.41) USP30DPP4KDM4EHPGDALDH1A1
SCHEMBL3370504 0.79 CYP2C19 (0.43) KDM4EHPGDALDH1A1HSD11B1MAPT
SCHEMBL3368142 0.78 CYP2C19 (0.44) USP30DPP4KDM4EHPGDALDH1A1
SCHEMBL3369442 0.77 ALDH1A1 (0.44) USP30KDM4EALDH1A1HCRTR1HCRTR2
SCHEMBL3364395 0.76 ALDH1A1 (0.49) USP30ALDH1A1TNKSPARP1PARP2
SCHEMBL3366814 0.75 KDM4E (0.41) KDM4EHPGDALDH1A1HSD11B1MAPT
SCHEMBL3367261 0.75 SMN1; SMN2 (0.41) KDM4EHPGDALDH1A1HSD11B1HCRTR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1532141-B1 2-PYRROLIDIN-2-YL- [1,3,4]-OXADIAZOLE DERIVATIVES AND THE USE OF THE SAME AS ANTIDEPRESSANTS GRUENENTHAL GMBH (DE) 2010-10-13 EP disclosed
US-7105538-B2 2-pyrrolidin-2-yl-[1,3,4]-oxadiazole compounds and their use as anti-depressants GRUENENTHAL GMBH (DE) 2006-09-12 US disclosed
US-20050187260-A1 2-Pyrrolidin-2-yl-[1,3,4]-oxadiazole compounds and their use as anti-depressants GRUENENTHAL GMBH (DE) 2005-08-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050187260-A1 2-Pyrrolidin-2-yl-[1,3,4]-oxadiazole compounds and their use as anti-depressants OPRD1, OPRK1, GRIN2C USP30 3920/4885DPP4 1020/4885HDAC1 282/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.